---
title: "Guggenheim Remains a Buy on Arcutis Biotherapeutics (ARQT)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293028760.md"
description: "Guggenheim reiterated a Buy rating on Arcutis Biotherapeutics (ARQT) with a $35 price target, while shares closed at $27.74. The broader analyst consensus is Strong Buy with an average target of $34.86, implying 25.67% upside. Mizuho Securities also maintained a Buy rating with a $35 target in a July 15 report."
datetime: "2026-07-17T11:16:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293028760.md)
  - [en](https://longbridge.com/en/news/293028760.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293028760.md)
generator: "portal-rs"
---

# Guggenheim Remains a Buy on Arcutis Biotherapeutics (ARQT)

Guggenheim analyst reiterated a Buy rating on Arcutis Biotherapeutics yesterday and set a price target of $35.00. The company’s shares closed yesterday at $27.74.

### TipRanks Welcomes a New ETF – NYSE:RANK

-   TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
-   RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcutis Biotherapeutics with a $34.86 average price target, a 25.67% upside from current levels. In a report released on July 15, Mizuho Securities also reiterated a Buy rating on the stock with a $35.00 price target.

### Related Stocks

- [ARQT.US](https://longbridge.com/en/quote/ARQT.US.md)
- [RANK.US](https://longbridge.com/en/quote/RANK.US.md)
- [MFG.US](https://longbridge.com/en/quote/MFG.US.md)
- [8411.JP](https://longbridge.com/en/quote/8411.JP.md)

## Related News & Research

- [Top Arcutis Executive Makes Notable Move With Latest Stock Sale](https://longbridge.com/en/news/296664320.md)
- [Arcutis Biotherapeutics director Howard G. Welgus sells 4,730 common shares for $123,835.71](https://longbridge.com/en/news/296400256.md)
- [Did Profitability, Higher 2026 Guidance, and New Commercial Leadership Just Recast Arcutis Biotherapeutics' (ARQT) Investment Narrative?](https://longbridge.com/en/news/295147038.md)
- [Arcutis Biotherapeutics (ARQT) Wins FDA Filing Acceptance For ZORYVE, Is The Discount Still Justified?](https://longbridge.com/en/news/293088142.md)
- [Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Patrick Burnett Sells 955 Shares of Stock](https://longbridge.com/en/news/295047702.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**